AR and prostate cancer: While Enzalutamide improves survival and quality of life of patients with castrate-resistant disease, which highlights the benefit of targeting the AR axis in CRPC, enzalutamide-resistant prostate cancer (ERPC) almost always develops which leads to widespread metastatic disease eventually bringing demise to prostate cancer patients4–6.